S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:TBPH

Theravance Biopharma Stock Forecast, Price & News

$19.45
+0.69 (+3.68 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.09
Now: $19.45
$19.53
50-Day Range
$16.57
MA: $18.66
$20.64
52-Week Range
$14.48
Now: $19.45
$31.35
Volume407,508 shs
Average Volume361,212 shs
Market Capitalization$1.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Theravance Biopharma logo

Headlines

Theravance Biopharma EPS beats by $0.10, misses on revenue
February 25, 2021 |  seekingalpha.com
Theravance Biopharma: Q4 Earnings Insights
February 24, 2021 |  finance.yahoo.com
Theravance Biopharma Earnings Preview
February 22, 2021 |  finance.yahoo.com
Is TBPH A Good Stock To Buy According To Hedge Funds?
December 19, 2020 |  finance.yahoo.com
Theravance Biopharma Is A Buy
December 2, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBPH
Previous SymbolNASDAQ:TBPHV
CUSIPN/A
Phone650-808-6000
Employees316
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$73.41 million
Book Value($3.94) per share

Profitability

Net Income$-236,460,000.00
Net Margins-345.16%

Miscellaneous

Market Cap$1.25 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

330th out of 1,972 stocks

Pharmaceutical Preparations Industry

155th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$19.45
+0.69 (+3.68 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

Is Theravance Biopharma a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Theravance Biopharma stock.
View analyst ratings for Theravance Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Theravance Biopharma?

Wall Street analysts have given Theravance Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Theravance Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Theravance Biopharma
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its earnings results on Monday, February, 22nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.02) by $0.10.
View Theravance Biopharma's earnings history
.

How has Theravance Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Theravance Biopharma's stock was trading at $24.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TBPH shares have decreased by 21.6% and is now trading at $19.45.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TBPH?

7 brokerages have issued 12 month price targets for Theravance Biopharma's shares. Their forecasts range from $29.00 to $42.00. On average, they anticipate Theravance Biopharma's stock price to reach $33.43 in the next twelve months. This suggests a possible upside of 71.9% from the stock's current price.
View analysts' price targets for Theravance Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the following people:
  • Mr. Rick E. Winningham M.B.A., Chairman & CEO (Age 61, Pay $1.46M)
  • Mr. Andrew Asa Hindman, Sr. VP & CFO (Age 48, Pay $706k)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 61, Pay $760k)
  • Dr. Brett K. Haumann, Sr. VP & Chief Medical Officer (Age 51, Pay $755.43k)
  • Mr. Frank Pasqualone, Sr. VP & Chief Bus. Officer (Age 65, Pay $752.4k)
  • Mr. Vijay Sabesan, Sr. VP of Technical Operations (Age 48)
  • Ms. Gail B. Cohen, VP of Corp. Communications & Investor Relations
  • Ms. Rhonda F. Farnum, VP of Sales & Marketing
  • Mr. Dennis O. Driver, Sr. VP of HR, Organizational and Leadership Devel.
  • Dr. Phillip D. Worboys, Sr. VP of Research & Translational Science (Age 51)

Who are some of Theravance Biopharma's key competitors?

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.02%), Norges Bank (1.03%), Laurion Capital Management LP (1.00%), Peregrine Capital Management LLC (0.86%), Northern Trust Corp (0.84%) and Price T Rowe Associates Inc. MD (0.70%). Company insiders that own Theravance Biopharma stock include Brett K Haumann, Donal O'connor, Philip D Worboys, Richard A Graham, Sharathchandra S Hegde and Vijay Sabesan.
View institutional ownership trends for Theravance Biopharma
.

Which major investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Northern Trust Corp, Hudson Bay Capital Management LP, Royce & Associates LP, Nuveen Asset Management LLC, Russell Investments Group Ltd., State of Wisconsin Investment Board, and Aperio Group LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Brett K Haumann, Philip D Worboys, and Richard A Graham.
View insider buying and selling activity for Theravance Biopharma
or view top insider-selling stocks.

Which major investors are buying Theravance Biopharma stock?

TBPH stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Laurion Capital Management LP, BlackRock Inc., Peregrine Capital Management LLC, Panagora Asset Management Inc., Tri Locum Partners LP, SG Americas Securities LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Theravance Biopharma
or or view top insider-buying stocks.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $19.45.

How much money does Theravance Biopharma make?

Theravance Biopharma has a market capitalization of $1.25 billion and generates $73.41 million in revenue each year. The biopharmaceutical company earns $-236,460,000.00 in net income (profit) each year or ($4.25) on an earnings per share basis.

How many employees does Theravance Biopharma have?

Theravance Biopharma employs 316 workers across the globe.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is www.theravance.com.

Where are Theravance Biopharma's headquarters?

Theravance Biopharma is headquartered at UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.